20 Jul 2017
In her new role, Ms. Butler will be responsible for driving the global launch and commercialization strategy of Tessa’s advanced T cell therapy pipeline. She will be based in the US and will be leading the expansion of the company’s US business operations.
19 Jun 2017
Unique collaboration model will leverage Parker Institute’s immunotherapy network and Tessa’s Virus Specific T Cell (VST) platform to create next generation cancer immunotherapy treatments. Tessa Therapeutics is the first cellular therapy partner company to form a multi-year alliance with the Parker Institute
02 Jun 2017
Biomarker data, from Tessa’s Phase II trial of lead candidate TT10, presented at the annual meeting of the American Society of Clinical Oncology (ASCO), 2017. The biomarkers are predictive of patient survival and response to CTL therapy, with exciting potential to drive more effective and better designed treatments
25 Apr 2017
Combination of Tessa’s Virus Specific T Cell (VST) platform and Vyriad’s oncolytic viruses are highly synergistic and have the potential to effectively target a broad range of hard-to-treat solid tumors
23 Mar 2017
The acquisition of Euchloe Bio, a company with an advanced antibody technology platform and a comprehensive portfolio of fully-human antibodies, strengthens Tessa’s position as a leading fully-integrated cancer immunotherapy company.
07 Feb 2017
Collaboration Will Leverage Tessa’s Expertise in Cancer Immunotherapy and A*STAR’s Research Capabilities to Create Next Generation Treatments for a Wide Range of Cancers.